|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2009-8-26
|
|
pubmed:abstractText |
Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, complete molecular responses are infrequent. The Bcr-Abl fusion creates a unique sequence of amino acids that could constitute a target for immunomodulation.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3924-34
|
|
pubmed:meshHeading |
pubmed-meshheading:19536894-Adult,
pubmed-meshheading:19536894-CD4 Lymphocyte Count,
pubmed-meshheading:19536894-Cancer Vaccines,
pubmed-meshheading:19536894-Combined Modality Therapy,
pubmed-meshheading:19536894-Female,
pubmed-meshheading:19536894-Fusion Proteins, bcr-abl,
pubmed-meshheading:19536894-Humans,
pubmed-meshheading:19536894-Immunophenotyping,
pubmed-meshheading:19536894-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19536894-Male,
pubmed-meshheading:19536894-Middle Aged,
pubmed-meshheading:19536894-Pilot Projects,
pubmed-meshheading:19536894-Piperazines,
pubmed-meshheading:19536894-Pyrimidines,
pubmed-meshheading:19536894-T-Lymphocyte Subsets,
pubmed-meshheading:19536894-Vaccines, Subunit,
pubmed-meshheading:19536894-Vaccines, Synthetic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
